Relationship of serum periostin with bone mineral density in maintenance hemodialysis patients

HU Yanqiu; TENG Jian; GONG Xue; XU Xiaona; WAN Meiyan

doi:10.7619/jcmp.20241416

Journal of Clinical Medicine in Practice > 2024 > 28(18): 106-110. > DOI: 10.7619/jcmp.20241416

HU Yanqiu, TENG Jian, GONG Xue, XU Xiaona, WAN Meiyan. Relationship of serum periostin with bone mineral density in maintenance hemodialysis patients[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 106-110. DOI: 10.7619/jcmp.20241416

Citation:

PDF (917 KB)

Relationship of serum periostin with bone mineral density in maintenance hemodialysis patients

1.
School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, 261000
2.
Department of Nephrology, Qingdao Municipal Hospital, Qingdao, Shandong, 266011
3.
Central Laboratory, Qingdao Municipal Hospital, Qingdao, Shandong, 266011

More Information

Received Date: April 07, 2024
Revised Date: June 02, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the relationship between serum periostin (POSTN) level and bone mineral density in patients undergoing maintenance hemodialysis (MHD).
Methods
Ninety-five patients who had received MHD treatment for more than 3 months in the Hemodialysis Center of Qingdao Municipal Hospital from October 2022 to October 2023 were enrolled as experimental group. Meanwhile, 50 healthy individuals undergoing health examinations in the Physical Examination Center of the same hospital during the same period were selected as the control group. Clinical data such as gender and age were collected for both groups. Fasting venous blood samples were collected before dialysis to measure parathyroid hormone (PTH), alkaline phosphatase (ALP), urea nitrogen, serum creatinine, serum calcium, serum phosphorus, and other indicators. Serum POSTN levels in MHD patients and healthy individuals were determined using enzyme-linked immunosorbent assay (ELISA). The correlation between serum POSTN levels and bone mineral density in MHD patients was explored. Univariate and multivariate binary Logistic regression analyses were performed to identify risk factors for low bone mineral density in MHD patients and assess the clinical value of serum POSTN level in predicting low bone mineral density in these patients.
Results
The serum POSTN level in the experimental group were significantly higher than those in the control group (P < 0.05). These patients were divided into two groups based on T-values: normal bone mass group(47 cases, T value >-1.0) and low bone mineral density (48 cases, T value≤-1.0). The low bone mineral density group had significantly higher serum POSTN levels, dialysis vintage, PTH, ALP, serum phosphorus, β₂-microglobulin levels, and a higher proportion of females compared to the normal bone mass group (P < 0.05). Pearson correlation analysis revealed negative correlations of bone mineral density T values with serum POSTN, dialysis vintage, C-reactive protein, PTH, ALP, serum phosphorus, and β₂-microglobulin in MHD patients (r=-0.695, -0.688, -0.246, -0.528, -0.216, -0.309, -0.293; P < 0.05). Multivariate binary Logistic regression analysis showed that after adjusting for confounding factors such as dialysis vintage, PTH, and ALP, high serum POSTN level was an independent risk factor for low bone mineral density in MHD patients. The receiver operating characteristic (ROC) curve indicated that the area under the curve (AUC) for serum POSTN level in predicting low bone mineral density in MHD patients was 0.901, with a cut-off value of 29.66 ng/L.
Conclusion
MHD patients have higher serum POSTN levels than healthy individuals, and this marker is associated with low bone mineral density in MHD patients.

FullText(HTML)

References (25)

References

[1]	SRIDHARAN K. Chronic kidney disease mineral and bone disorder: a guide for general practice[J]. Aust J Gen Pract, 2023, 52(1/2): 52-57.
[2]	黄雅云, 黄勇翔, 黄琴, 等. 阿法骨化醇联合血液灌流与血液透析对CKD-MBD患者肾功能的影响[J]. 吉林医学, 2024, 45(2): 430-432.
[3]	王吉萍, 朱俊雅, 吴丽华, 等. 碳酸司维拉姆联合血液透析和血液灌流治疗CKD-MBD的疗效及对患者微炎症状态和钙磷代谢的影响[J]. 海南医学, 2021, 32(10): 1248-1251. doi: 10.3969/j.issn.1003-6350.2021.10.007
[4]	FUSARO M, BARBUTO S, GALLIENI M, et al. Real-world usage of Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices[J]. Clin Kidney J, 2024, 17(1): sfad290. doi: 10.1093/ckj/sfad290
[5]	KAUR R, SINGH R. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications[J]. Life Sci, 2022, 311(Pt B): 121148.
[6]	PANǍ N, CǍPUŞǍ C. Periostin as a biomarker in the setting of glomerular diseases-a review of the current literature[J]. Biomedicines, 2022, 10(12): 3211. doi: 10.3390/biomedicines10123211
[7]	YANG L N, GUO T T, CHEN Y Y, et al. The multiple roles of periostin in non-neoplastic disease[J]. Cells, 2022, 12(1): 50. doi: 10.3390/cells12010050
[8]	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2022, 15(6): 573-611.
[9]	范思祺, 鲁美丽, 王洪新, 等. 基于骨膜素探讨黄芪甲苷对低氧诱导肺动脉高压小鼠的保护作用及机制[J]. 中药新药与临床药理, 2023, 34(1): 16-24.
[10]	梅玉霞, 刘小敏, 陆振瑜, 等. 定喘汤联合穴位贴敷对小儿咳嗽变异性哮喘患儿血清骨膜素、sST2和CC-16水平的影响[J]. 检验医学与临床, 2022, 19(4): 532-536.
[11]	廖强, 王娟. 骨质疏松患者血清25(OH) D, 骨膜素、铁蛋白水平及其与骨折发生的相关性分析[J]. 现代检验医学杂志, 2021, 36(05): 138-142.
[12]	WANG Z, AN J, ZHU D, et al. Periostin: an emerging activator of multiple signaling pathways[J]. J Cell Commun Signal, 2022, 16(4): 515-530.
[13]	KO F C, XIE R, WILLIS B, et al. Cells transiently expressing periostin are required for intramedullary intramembranous bone regeneration[J]. Bone, 2024, 178: 116934.
[14]	YAN Z H, WANG G R, SHI X Y. Advances in the progression and prognosis biomarkers of chronic kidney disease[J]. Front Pharmacol, 2021, 12: 785375.
[15]	HU L, NAPOLETANO A, PROVENZANO M, et al. Mineral bone disorders in kidney disease patients: the ever-current topic[J]. Int J Mol Sci, 2022, 23(20): 12223.
[16]	夏凤芝, 张凯, 慢性肾脏病患者骨质疏松和心血管钙化情况与骨代谢标志物的相关性[J]. 内科, 2023, 18(6): 543-547.
[17]	赵传燕, 刘昌华, 毕光宇, 等. 血清胃泌素前体释放肽在慢性肾脏病中的临床意义与诊断价值[J]. 实用临床医药杂志, 2022, 26(5): 62-65, 70. doi: 10.7619/jcmp.20213325
[18]	李晓东, 周萍. 慢性肾脏病蛋白质能量消耗的发病机制及防治策略[J]. 实用临床医药杂志, 2021, 25(7): 118-122. doi: 10.7619/jcmp.20210465
[19]	BELLORIN-FONT E, ROJAS E, MARTIN K J. Bone disease in chronic kidney disease and kidney transplant[J]. Nutrients, 2022, 15(1): 167.
[20]	BONNET N, STANDLEY K N, BIANCHI E N, et al. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity[J]. J Biol Chem, 2009, 284(51): 35939-35950.
[21]	BONNET N, DOUNI E, PERRÉARD LOPRENO G, et al. RANKL-induced increase in cathepsin K levels restricts cortical expansion in a periostin-dependent fashion: a potential new mechanism of bone fragility[J]. J Bone Miner Res, 2021, 36(8): 1636-1645.
[22]	LI C R, LI X, WANG X, et al. Periostin mediates oestrogen-induced osteogenic differentiation of bone marrow stromal cells in ovariectomised rats[J]. Biomed Res Int, 2020, 2020: 9405909.
[23]	LIU S L, JIN Z L, CAO M, et al. Periostin regulates osteogenesis of mesenchymal stem cells from ovariectomized rats through actions on the ILK/Akt/GSK-3β Axis[J]. Genet Mol Biol, 2021, 44(3): e20200461.
[24]	GUO Y M, CHENG J H, ZHANG H, et al. Serum periostin level and genetic polymorphisms are associated with vertebral fracture in Chinese postmenopausal women[J]. Genes, 2022, 13(3): 439.
[25]	PIMENTEL A, BOVER J, ELDER G, et al. The use of imaging techniques in chronic kidney disease-mineral and bone disorders (CKD-MBD)-a systematic review[J]. Diagnostics, 2021, 11(5): 772.

[1]	FENG Yu, ZHANG Kaigui, ZHU Maocai, ZOU Zhaohua, QING Wei. Risk factor analysis and personalized prevention strategies for renal anemia in hemodialysis patients with end-stage kidney disease[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 103-109. DOI: 10.7619/jcmp.20244557
[2]	TIAN Qianqian, WU Qiuchan, FENG Yuanjun, ZHANG Zulong, LI Mei, ZHANG Xuan, XIE Moujin, QING Qunchao, LIU Lei. Impact of Coronavirus Disease 2019 on long-term renal function in patients with chronic kidney disease undergoing no renal replacement therapy[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 86-89, 94. DOI: 10.7619/jcmp.20242826
[3]	ZHOU Manman, XU Zhiqiang, GAO Wenwen, LI Yidi, FU Juan, YANG Gaiqing. Correlations of serum osteocalcin level and bone mineral density with depression status in patients with Parkinson′s disease[J]. Journal of Clinical Medicine in Practice, 2023, 27(21): 125-130. DOI: 10.7619/jcmp.20232695
[4]	CAI Qian, ZHANG Zulong. Analysis in related influencing factors of sarcopenia in patients with maintenance hemodialysis for end-stage renal disease[J]. Journal of Clinical Medicine in Practice, 2023, 27(10): 84-90. DOI: 10.7619/jcmp.20230632
[5]	LI Xinli, SHEN Lei, LU Yuan, FEI Mei, LI Jianzhong, XU Deyu, ZHOU Ling, LU Guoyuan. Evaluation value of systemic immune inflammation index for left ventricular hypertrophy in non-dialysis patients with chronic kidney disease[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 44-49. DOI: 10.7619/jcmp.20213497
[6]	LI Xiaodong, ZHOU Ping. Pathogenesis of protein energy wasting in chronic kidney disease and its prevention strategy[J]. Journal of Clinical Medicine in Practice, 2021, 25(7): 118-122. DOI: 10.7619/jcmp.20210465
[7]	SUN Jing, DU Xuanyi. Research progress in pathogenesis and treatment of hyperkalemia in chronic kidney disease[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 125-128. DOI: 10.7619/jcmp.20201152
[8]	ZHANG Baizhong, HAN Qing, MA Chunyuan. Investigation in serum minerals and bone disorder in patients with chronic kidney disease at stages 5 and 5D[J]. Journal of Clinical Medicine in Practice, 2021, 25(4): 89-92. DOI: 10.7619/jcmp.20200838
[9]	CHEN Xiao, NIE Anqi, LIU Jing, LU Yuqing, SHI Jiaqi, CHEN Xiaolan. Advances in exosomes microRNA in chronic kidney disease[J]. Journal of Clinical Medicine in Practice, 2020, 24(24): 128-132. DOI: 10.7619/jcmp.202024039
[10]	WU Guangbiao. Effect of hemodialysis combined with hemoperfusion in the treatment of patients with chronic kidney disease-mineral and bone disorder[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 110-112. DOI: 10.7619/jcmp.202010028

Cited By

Cited by

Periodical cited type(16)

1.	肖梦，肖建明，沈倩. 专科化游戏干预在烧伤植皮患儿围手术期护理中的应用. 中国美容医学. 2024(03): 171-174 .
2.	蒋敏. 家长协同游戏式多维康复训练对儿童四肢骨折术后康复的影响. 当代护士(上旬刊). 2024(04): 36-40 .
3.	陈侃，周婷婷. 术前模拟游戏联合集束化护理干预在儿童手术患者中的应用价值. 中国当代医药. 2023(07): 169-172 .
4.	董金萍. 可视音乐联合游戏护理模式对过敏性紫癜患儿情绪状态、生活质量的影响分析. 黑龙江医学. 2023(10): 1259-1261 .
5.	杨杨，卢丹，纪萌. 个性化心理护理对青少年阴茎包皮手术治疗效果的影响. 潍坊医学院学报. 2023(03): 224-226 .
6.	李秋蝉，郭巧玲，何静. 游戏护理模式在内窥镜下扁桃体切除术患儿中的应用效果. 中国卫生标准管理. 2023(15): 176-181 .
7.	宋玲. 综合护理干预在小儿疝气手术护理中的应用效果. 妇儿健康导刊. 2023(15): 189-191 .
8.	吴舜英，洪冬梅，苏花治. 小儿隐匿性阴茎术后疼痛的围手术期优质护理应用效果探讨. 当代医学. 2022(05): 176-178 .
9.	宣雪. 专科化游戏结合双心护理对腹腔镜手术患儿术后依从性的影响. 航空航天医学杂志. 2022(03): 350-352 .
10.	肖娅，罗金文，周丽欢. 多媒体互动宣教联合体贴式护理对微创漏斗胸矫治术患儿的影响. 护理实践与研究. 2022(10): 1421-1426 .
11.	邹旭露. 游戏管理模式在小儿巨结肠围术期的应用效果. 中国肛肠病杂志. 2022(05): 71-72 .
12.	张瑛，邢璐. 情景游戏联合家属互补式健康宣教对6～8岁支原体肺炎患儿的应用效果. 河南医学研究. 2022(15): 2866-2870 .
13.	孙蕾，金薇，王楠. 情志干预下寓教于乐模式护理对小儿发育性髋关节脱位矫形术后肢体恢复及疼痛影响. 中国医药导报. 2022(33): 168-171 .
14.	陈晓月，李娜. 游戏护理模式在小儿肠梗阻围术期中的应用效果. 现代诊断与治疗. 2021(02): 309-310 .
15.	张晓华，朱凌倩，易小芬，钟芳萍，杨霞，郭晓云. 模拟Child life干预在儿童反复呼吸道感染中的作用. 中国当代医药. 2021(18): 274-276 .
16.	吴雪芳. 图文沟通措施对美克尔憩室手术治疗患儿的护理效果分析. 当代医学. 2021(27): 65-67 .

Other cited types(0)

Get Citation

PDF

XML

Article views (97) PDF downloads (8) Cited by(16)

Turn off MathJax

Article Contents

Abstract

References

Relationship of serum periostin with bone mineral density in maintenance hemodialysis patients